KCC Referral
Management System
Shared Care
Guidelines
Care Home
Resources
Local Resource
Packs
Chronic Pain
in Cornwall
Diabetes Resources
Respiratory Resources
Flu Resource Pack
Patient Group Direction (PGD)
Palliative Care Resources
Search   
        Click to View ALL BNF
 >>  >> 
   (Click to View Drug List)


Cost
Packs
Items
Other - Cost: £680,504,932.21 Glucose interstitial detection sensor (FreeStyle Libre 2 Plus Sensor) - Cost: £11,120,962.50 Trimbow - Cost: £11,787,827.50 Beclometasone / Formoterol MDI (Fostair) - Cost: £12,847,965.36 FreeStyle Libre 2 Sensor - Cost: £13,698,650.00 Empagliflozin (Jardiance) - Cost: £14,849,619.46 Tirzepatide (Mounjaro KwikPen) - Cost: £18,019,462.00 Edoxaban (Lixiana) - Cost: £19,124,780.50 Dapagliflozin (Forxiga) - Cost: £30,811,067.91
Formulary Notes (BNF Chapter)
NICE Guidance (8)
Other Links (3)
Important Local Documents (1)

Cornwall Joint Formulary Recommended Choices     (...Top)
Displaying 2 Drugs

Key:
First Line Drugs First Line Drugs
Second Line Drugs Second Line Drugs
Specialist advised Specialist advised
Specialist Initiated Drugs Specialist Initiated Drugs
Hospital Only Drugs Hospital Only Drugs
Discouraged Discouraged
No comment available No comment available

NameTariffBNF Sub Paragraph
Nirmatrelvir / Ritonavir (Paxlovid)
150 mg/100mg tablets Pack of 30		£829.00PCT FORMULARY STATUS: First Line Drugs [Notes:] May 2025 national update: Withdrawal of recommendation to expand use of Paxlovid to additional patient groups (NICE TA878). Paxlovid is now recommended for use only in patients at increased risk of progression to severe COVID-19 (patient groups defined in TA878 - section 5). CoronavirusView BNF Article on 'Nirmatrelvir / Ritonavir'View SPC on 'Nirmatrelvir / Ritonavir'View PIL on 'Nirmatrelvir / Ritonavir'
May 2025 national update: Withdrawal of recommendation to expand use of Paxlovid to additional patient groups (NICE TA878). Paxlovid is now recommended for use only in patients at increased risk of progression to severe COVID-19 (patient groups defined in TA878 - section 5).
Molnupiravir
200 mg capsules No price on DM+D as of 4/3/2022 Pack of 40		£0.01PCT FORMULARY STATUS: Second Line Drugs [Notes:] Available to order Free of Charge from Alliance Healthcare 2023/2024 Where treatment with both Paxlovid and sotrovimab are both contraindicated or not clinically suitable AND treatment with remdesivir is contraindicated, not clinically suitable or not available, as per NHSE policy  CoronavirusView BNF Article on 'Molnupiravir'View SPC on 'Molnupiravir'View PIL on 'Molnupiravir'
Available to order Free of Charge from Alliance Healthcare 2023/2024 Where treatment with both Paxlovid and sotrovimab are both contraindicated or not clinically suitable AND treatment with remdesivir is contraindicated, not clinically suitable or not available, as per NHSE policy

 
© Kernow Clinical Commissioning Group 2025 - All Rights Reserved
The Sedgemoor Centre, Priory Road, St Austell, Cornwall, PL25 5AS